Human Genome Sciences, Inc (HGSI)

[chmcnfunds]

5 Biotech Stocks Ready To Rise On New Treatments

April 18, 2012

I believe one of the keys to smart biotech investing is to focus on companies that are treating chronic diseases. Instead of looking to cure something, the treatments developed and marketed by these companies will help patients manage symptoms. This ensures long-term success and allows you to invest your money in a company that is protecting its own security. There are five standout companies in the biotech industry that I consider the best bets for those who want a long term, steady earner.

The first company I have been watching for awhile is Human Genome Sciences (HGSI). The company is poised to make a big splash in 2012, due to its focus on treatments that will affect the baby boomer generation. The company reached a 52-week high of $30 per share at one point, but plummeted to just $6 per share in the last year. The price is currently around $7. HGSI released Benlysta in 2011, a treatment for adult patients with active systemic lupus who are currently receiving standard therapy. Benlysta was the first drug approved to treat lupus in more than 50 years and I believe it will bring steady earnings in the upcoming months. Lupus is a chronic disease, so Benlysta sales are predicted to be steady.

In addition to Benlysta, HGSI, in conjunction with GlaxoSmithKline (GSK), reported successful results from phase 3 trials of a drug intended to treat Type 2 diabetes. An April news release provided more information about the testing, showing seven of its eight Harmony Phase III trials as successful.
_________________________________________________
http://seekingalpha.com/article/506001-5-biotech-stocks-ready-to-rise-on-new-treatments

HGSI